Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | RYZB | Common Stock | Conversion of derivative security | +1.56M | 1.56M | Sep 19, 2023 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | RYZB | Series D Preferred Stock | Conversion of derivative security | $0 | -1.56M | -100% | $0.00* | 0 | Sep 19, 2023 | Common Stock | 1.56M | Direct | F1 |
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date. |